Ardelyx Inc. is dedicated to developing first-in-class medicines aimed at addressing significant unmet medical needs, particularly in the areas of chronic kidney disease with hyperphosphatemia and irritable bowel syndrome with constipation (IBS-C). The company focuses on innovative therapeutic approaches that improve patient outcomes and quality of life. Their commitment to patient care is evident in their collaborative efforts with patients and caregivers, ensuring that their insights and needs are integral to the development of new treatments. Ardelyx emphasizes the importance of community engagement and product innovation as part of their mission to enhance healthcare.

The company conducts clinical trials as a critical component of their research and development process. These trials are designed to evaluate the safety and efficacy of their medications, such as tenapanor, which is being studied for its effects on IBS-C in pediatric patients. Ardelyx places a strong emphasis on diversity, equity, and inclusion in their clinical trials, recognizing the importance of recruiting participants that reflect the demographics of the patient populations they aim to serve. This approach not only enhances the understanding of treatment effectiveness but also ensures that the therapies developed are safe and effective for a broad range of patients.

United States

Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. 

Community Guidelines: https://rb.gy/07ltg3

Digestive System Diseases

Kidney Diseases

Metabolic Diseases

Ardelyx Inc.

Chronic kidney disease

Electrolyte disorder

Hyperphosphatemia

Kidney disease

Tenapanor is a first-in-class, targeted small molecule with a &nbsp;unique mechanism of action that blocks the paracellular absorption of &nbsp;phosphate in the GI tract rather than binding it, creating the potential &nbsp;to completely change the treatment paradigm.

XPHOZAH (Tenapanor) (Phosphate Absorption Inhibitor) 

Constipation

Irritable bowel syndrome

IBSRELA (tenapanor) is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible for the absorption of dietary sodium. In vitro and animal studies indicate its major metabolite, M1, is not active against NHE3. By inhibiting NHE3 on the apical surface of the enterocytes, tenapanor reduces absorption of sodium from the small intestine and colon, resulting in an increase in water secretion into the intestinal lumen, which accelerates intestinal transit time and results in a softer stool consistency.
Tenapanor has also been shown to reduce abdominal pain by decreasing visceral hypersensitivity and by decreasing intestinal permeability in animal models. In rat model of colonic hypersensitivity, tenapanor reduced visceral hyperalgesia and normalized colonic sensory neuronal excitability.

Tenapanor (Ibsrela) (NHE3 sodium transport inhibitor)

Hyperkalemia

Unlike current treatments that bind potassium, our lead candidate &nbsp;in the RDX013 program represents a first-in-class, targeted therapy that &nbsp;could create a completely new treatment paradigm for patients with &nbsp;hyperkalemia if successfully developed.
RDX013 is a program that pharmacologically targets &nbsp;potassium secretion through the lumen of the gut, thus lowering levels &nbsp;of serum potassium.

Ardelyx Inc.

Company Details